Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. - Archive ouverte HAL Access content directly
Journal Articles Journal of Translational Medicine Year : 2009

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

(1) , (1) , (2) , (3) , (4) , (5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (14) , (15) , (16) , (16) , (2) , (1) , (1) , (17) , (18) , (19) , (4) , (20) , (20) , (21) , (22) , (23, 24) , (25) , (26) , (11) , (27) , (18) , (28) , (12) , (21) , (3) , (29) , (30) , (31) , (28) , (32) , (33) , (34) , (35) , (36) , (13) , (37) , (21) , (19) , (38) , (39) , (40) , (3)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Magdalena Thurin
  • Function : Correspondent author
  • PersonId : 899090

Connectez-vous pour contacter l'auteur
Mary Disis
  • Function : Author
  • PersonId : 899093
Peter Lee
  • Function : Author
  • PersonId : 899095
Samir Khleif
  • Function : Author
  • PersonId : 899096
Jon Wigginton
  • Function : Author
  • PersonId : 899097
Stefan Ambs
  • Function : Author
  • PersonId : 899098
Yasunori Akutsu
  • Function : Author
  • PersonId : 899099
Damien Chaussabel
  • Function : Author
  • PersonId : 899100
Yuichiro Doki
  • Function : Author
  • PersonId : 899101
Oleg Eremin
  • Function : Author
  • PersonId : 899102
Wolf Hervé Fridman
  • Function : Author
  • PersonId : 899103
Yoshihiko Hirohashi
  • Function : Author
  • PersonId : 899104
Kohzoh Imai
  • Function : Author
  • PersonId : 899105
James Jacobson
  • Function : Author
  • PersonId : 899106
Masahisa Jinushi
  • Function : Author
  • PersonId : 899107
Akira Kanamoto
  • Function : Author
  • PersonId : 899108
Mohammed Kashani-Sabet
  • Function : Author
  • PersonId : 899109
Kazunori Kato
  • Function : Author
  • PersonId : 899110
Yutaka Kawakami
  • Function : Author
  • PersonId : 899111
Thomas Kleen
  • Function : Author
  • PersonId : 899113
Paul Lehmann
  • Function : Author
  • PersonId : 899114
Michael Lotze
  • Function : Author
  • PersonId : 899116
Anatoli Malyguine
  • Function : Author
  • PersonId : 899118
Giuseppe Masucci
  • Function : Author
  • PersonId : 899119
Hisahiro Matsubara
  • Function : Author
  • PersonId : 899120
Shawmarie Mayrand-Chung
  • Function : Author
  • PersonId : 899121
Kiminori Nakamura
  • Function : Author
  • PersonId : 899122
a Karolina Palucka
  • Function : Author
  • PersonId : 899124
Zoltan Pos
  • Function : Author
  • PersonId : 899126
Antoni Ribas
  • Function : Author
  • PersonId : 899127
Licia Rivoltini
  • Function : Author
  • PersonId : 899128
Noriyuki Sato
  • Function : Author
  • PersonId : 899129
Craig Slingluff
  • Function : Author
  • PersonId : 899131
Howard Streicher
  • Function : Author
  • PersonId : 899132
David Stroncek
  • Function : Author
  • PersonId : 899133
Hiroya Takeuchi
  • Function : Author
  • PersonId : 899134
Minoru Toyota
  • Function : Author
  • PersonId : 899135
Hisashi Wada
  • Function : Author
  • PersonId : 899136
Xifeng Wu
  • Function : Author
  • PersonId : 899137
Tomonori Yaguchi
  • Function : Author
  • PersonId : 899139
Benjamin Zeskind
  • Function : Author
  • PersonId : 899140
Yingdong Zhao
  • Function : Author
  • PersonId : 899141
Mai-Britt Zocca
  • Function : Author
  • PersonId : 899142

Abstract

Supported by the Office of International Affairs, National Cancer Institute (NCI), the "US-Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009. The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy. The effort will culminate on October 28th 2009 in the "iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", which will be held in Washington DC in association with the Annual Meeting. The purposes of the US-Japan workshop were a) to discuss novel approaches to enhance the discovery of predictive and/or prognostic markers in cancer immunotherapy; b) to define the state of the science in biomarker discovery and validation. The participation of Japanese and US scientists provided the opportunity to identify shared or discordant themes across the distinct immune genetic background and the diverse prevalence of disease between the two Nations. Converging concepts were identified: enhanced knowledge of interferon-related pathways was found to be central to the understanding of immune-mediated tissue-specific destruction (TSD) of which tumor rejection is a representative facet. Although the expression of interferon-stimulated genes (ISGs) likely mediates the inflammatory process leading to tumor rejection, it is insufficient by itself and the associated mechanisms need to be identified. It is likely that adaptive immune responses play a broader role in tumor rejection than those strictly related to their antigen-specificity; likely, their primary role is to trigger an acute and tissue-specific inflammatory response at the tumor site that leads to rejection upon recruitment of additional innate and adaptive immune mechanisms. Other candidate systemic and/or tissue-specific biomarkers were recognized that might be added to the list of known entities applicable in immunotherapy trials. The need for a systematic approach to biomarker discovery that takes advantage of powerful high-throughput technologies was recognized; it was clear from the current state of the science that immunotherapy is still in a discovery phase and only a few of the current biomarkers warrant extensive validation. It was, finally, clear that, while current technologies have almost limitless potential, inadequate study design, limited standardization and cross-validation among laboratories and suboptimal comparability of data remain major road blocks. The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions.
Fichier principal
Vignette du fichier
1479-5876-7-45.pdf (682.79 Ko) Télécharger le fichier
Vignette du fichier
1479-5876-7-45.xml (497.34 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Loading...

Dates and versions

inserm-00585733 , version 1 (13-04-2011)

Identifiers

Cite

Hideaki Tahara, Marimo Sato, Magdalena Thurin, Ena Wang, Lisa Butterfield, et al.. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.. Journal of Translational Medicine, 2009, 7 (1), pp.45. ⟨10.1186/1479-5876-7-45⟩. ⟨inserm-00585733⟩
502 View
718 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More